2.0
Oct 9, 2011
Current employee
Recommend
CEO approval
Business outlook
Pros
Excellent pipeline that has a lot of potential. The oncology, RA, and biotech portfolios are really making inroads and will have a significant impact on patient treatment.
Cons
Constant downsizing & restructuring leaves you always wondering when you'll be next to go. Pfizer still seems unprepared for Lipitor patent cliff.